Eira Bio
Eira Bio is a biotechnology company developing breakthrough antibody-based therapeutics against challenging multi-pass membrane proteins, including GPCRs, ion channels, and solute transporters — targets that have long eluded traditional antibody discovery approaches. By combining powerful synthetic biology and directed-evolution platforms (like OrthoRep) with deep biologics and drug development expertise, Eira Bio makes rare antibody discovery routine and develops novel transformative therapies in areas of high unmet medical need.
The company’s scalable yeast-based discovery and optimization engines enable rapid generation of high-precision antibodies that were previously inaccessible, accelerating the path from early research to differentiated therapeutic product candidates. Through this innovation, Eira Bio aims to shift the drug development landscape for diseases that have resisted conventional approaches and expand the frontier of next-generation biologics.